Creative Commons source reading · Clinical neurodiagnostics
Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
Lauren M Byrne; Filipe B Rodrigues; Kaj Blennow; Alexandra Durr; Blair R Leavitt; Raymund A C Roos; Rachael I Scahill; Sarah J Tabrizi; Henrik Zetterberg; Douglas Langbehn; Edward J Wild
Originally published in The Lancet. Neurology · 2017-06-07
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background Blood biomarkers of neuronal damage could facilitate clinical management of and therapeutic development for Huntington's disease. We investigated whether neurofilament light protein NfL (also known as NF-L) in blood is a potential prognostic marker of neurodegeneration in patients with Huntington's disease. Methods We did a retrospective analysis of healthy controls and carriers of CAG expansion mutations in HTT participating in the 3-year international TRACK-HD study. We studied associations between NfL concentrations in plasma and clinical and MRI neuroimaging findings, namely cognitive function, motor function, and brain volume (global and regional). We used random effects models to analyse cross-sectional associations at each study visit and to assess changes from baseline, with and without adjustment for age and CAG repeat count. In an independent London-based cohort of 37 participants (23 HTT mutation carriers and 14 controls), we further assessed whether concentrations of NfL in plasma correlated with those in CSF. Findings Baseline and follow-up plasma samples were available from 97 controls and 201 individuals carrying HTT mutations.
Results
Of 366 TRACK-HD participants, baseline and follow-up plasma samples were available from 298 (81%) who completed the 3-year TRACK-HD study (97 controls and 201 HTT mutation carriers—58 with early premanifest and 46 with late premanifest disease, and 66 with stage 1 and 31 with stage 2 Huntington's disease). 293 had paired plasma samples from the 3-year follow-up visit, four from the 2-year visit, and one from the 1-year visit. The demographic and clinical characteristics of participants at baseline are presented in the appendix.
Discussion
In this genetically homogeneous cohort of HTT mutation carriers, uniquely large and well characterised among neurodegenerative disease cohorts, we found that NfL concentrations in plasma are increased compared with controls. Additionally, concentrations increased with advancing disease—most steeply in participants with premanifest Huntington's disease at baseline—and with increasing CAG triplet repeat counts. The concentration at a given timepoint reflected the degree of motor and cognitive impairment as well as global and regional brain volumes.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
